RxDoctor Payments Data

Jennifer Young, MD

Urology · Leesburg, VANPI 1740479971

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,375 of the $16,081 with a category attached, or 70.7%. Intuitive Surgical accounts for 86.8% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2024 at $9,451 and has fallen 97.4% since, to $250 in 2025.

$16,081in general payments, 2019–2025

Across 63 payments — averaging $255.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$14K
  • Johnson & Johnson$460
  • Procept Biorobotics Corporation$255
  • Axonics, Inc.$229
  • Boston Scientific$205
  • Sumitomo Pharma America, Inc.$189
  • plus $789 from 16 others

What the payments were for

  • Consulting fees$11,37571%
  • Travel & lodging$2562%
  • Food & beverage$2,20014%
  • Education$2,25014%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,081 in reported general payments places this provider in the 85th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$263,219
Medicare patients
461
Services billed
4,601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix110$308,281
NubeqaDarolutamide19$276,802
MyrbetriqMirabegron32$21,946
GemtesaVibegron15$7,551
Tamsulosin Hcl263$3,421
Potassium Citrate ErPotassium Citrate21$3,340
Methenamine Hippurate13$1,147
Finasteride109$935
Imipramine Hcl45$669
Tadalafil18$567
Oxybutynin Chloride ErOxybutynin Chloride13$238
Ciprofloxacin Hcl44$145
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst14$123
Alendronate Sodium17$76
Ibuprofen14$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$189$315,833125 claims
Astellas Pharma US IncMyrbetriq$80$21,94632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 300 urology providers in Virginia.

Other urology in Leesburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →